(NASDAQ: TERN) Terns Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.87%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 35.3%.
Terns Pharmaceuticals's earnings in 2026 is -$96,207,000.On average, 13 Wall Street analysts forecast TERN's earnings for 2026 to be -$137,030,320, with the lowest TERN earnings forecast at -$167,395,584, and the highest TERN earnings forecast at -$96,947,249. On average, 11 Wall Street analysts forecast TERN's earnings for 2027 to be -$173,708,696, with the lowest TERN earnings forecast at -$205,851,326, and the highest TERN earnings forecast at -$118,760,380.
In 2028, TERN is forecast to generate -$207,628,692 in earnings, with the lowest earnings forecast at -$262,403,888 and the highest earnings forecast at -$151,480,077.